Leigh Ann Bruhn, director of Avalere Health, addresses results from "DIMENSIONS of Specialty Pharmaceuticals: Evolving Trends in Market Access," a new study conducted by Avalere Health and commissioned by Janssen Biotech, Inc. and Johnson & Johnson Health Care Systems.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More